- $631.35m
- $519.81m
- $311.71m
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce
U.S. STOCKS ON THE MOVE-Cerebras, Madison Square Garden Sports
CorMedix Inc. reports results for the quarter ended June 30 - Earnings Summary
CorMedix rises on Q2 revenue beat
CorMedix beats Q2 revenue estimates on DefenCath growth, raises FY adjusted EBITDA guidance
CorMedix Q1 results beat on Defencath sales, raises outlook
Brief: Cormedix Therapeutics Announces Positive Topline Results From Phase Iii Respect Trial
Pharmaceutical firm CorMedix misses Q4 profit expectations, reiterates 2026 revenue forecast
Brief: Cormedix Therapeutics Announces Leadership And Board Updates
Brief: Cormedix Therapeutics Announces Preliminary Fourth Quarter And Full Year 2025 Results
Brief: Cormedix Reports Positive Data From Real World Study of Defencath
U.S. RESEARCH ROUNDUP-Abbvie, BristolMyers Squibb, Diversified Healthcare
U.S. STOCKS ON THE MOVE-TransDigm, Citigroup, Cisco Systems
U.S. STOCKS ON THE MOVE-Floor & Decor, Starbucks, gold miners
U.S. STOCKS ON THE MOVE-ExxonMobil, Yatra, Venture Global
CorMedix up after FY revenue guidance raise
Biopharma firm CorMedix's Q3 net income beats expectations
Biopharma firm CorMedix's preliminary Q3 revenue beats estimates, raises FY guidance